Table 1.
Transcript | bLR-VEH vs. bHR-VEH | bLR-FGF2 vs. bLR-VEH |
---|---|---|
CTGF | Upa | Downa |
ECM2 | Down | |
EGR1 | Downa | |
BCL2L2 | Upa | Upa |
IGFBP7 | Up | Downa |
P4HA1 | Downa | |
PDGFβ | Down | |
MAPKAPK5 | Upa | |
MAPK8IP3 | Upa | |
PKN1 | Upa | |
PRKAG1 | Upa | |
CREB1 | Down | |
RHOG | Upa | |
RHOA | Downa | Upa |
SOX4 | Upa | |
STK3 | Upa |
BCL2L2, Bcl-2-like protein 2; bHR, bred high responder; bLR, bred low responder; CREB1, cyclic adenosine monophosphate response element binding protein 1; CTGF, connective tissue growth factor; ECM2, extracellular matrix protein 2; EGR1, early growth response protein 1; IGFBP7, insulin-like growth factor–binding protein 7; MAPK8IP3, mitogen-activated protein kinase 8 interacting protein 3; MAPKAPK5, mitogen-activated protein kinase–activated protein kinase 5; P4HA1, prolyl 4-hydroxylase subunit alpha-1; PKN1, protein kinase novel 1; PRKAG1, protein kinase adenosine monophosphate–activated noncatalytic subunit gamma 1; PGDFβ, platelet-derived growth factor-β; RHOA, Ras homolog gene family member G; RHOG, homolog gene family member G; SOX4, (sex determining region Y)-box 4; STK3, serine/threonine kinase 3; VEH, vehicle.
Significant effects (p < .05).